RNA (Atrium Therapeutics) Total Assets: $292.36 Mil (As of Mar. 2026)


RNA Atrium Therapeutics Inc RNA
12 GF Score
Price $12.80
! 1 Warning Sign
View Full Analysis

What is Atrium Therapeutics Total Assets?

Atrium Therapeutics RNA +0.16% 12 Total Assets is $292.36 Mil as of Mar. 2026. GuruFocus rates RNA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Atrium Therapeutics's Total Assets for the quarter that ended in Mar. 2026 was $292.36 Mil.

During the past 12 months, Atrium Therapeutics's average Total Assets Growth Rate was 16.20% per year.

Total Assets is connected with ROA %. Atrium Therapeutics's annualized ROA % for the quarter that ended in Mar. 2026 was -23.32%. Total Assets is also linked to Revenue through Asset Turnover. Atrium Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 was 0.07.

Atrium Therapeutics  (NAS:RNA) Total Assets Explanation

Total Assets is connected with ROA %.

Atrium Therapeutics's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-66.532/( (278.353+292.36)/ 2 )
=-66.532/285.3565
=-23.32 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Atrium Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=19.635/( (278.353+292.36)/ 2 )
=19.635/285.3565
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Atrium Therapeutics Total Assets Related Terms

Atrium Therapeutics Total Assets Historical Data

* Premium members only.

The historical data trend for Atrium Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atrium Therapeutics Total Assets Chart

Atrium Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Total Assets
10.29 7.19 278.35

Atrium Therapeutics Quarterly Data
Dec23 Dec24 Mar25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial 7.19 0.00 277.54 278.35 292.36
RNA
12GF Score
Atrium Therapeutics Inc RNA
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atrium Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Atrium Therapeutics's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=207.287+71.066
=278.35

Atrium Therapeutics's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=234.104+58.256
=292.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $292.36 Mil mean?
Atrium Therapeutics (RNA) has a Total Assets of $292.36 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Atrium Therapeutics and its competitors.
Is Atrium Therapeutics' Total Assets too high?
Atrium Therapeutics' current Total Assets is $292.36 Mil. Overall, Atrium Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Atrium Therapeutics' Total Assets compare to RNAC and KROS?
Atrium Therapeutics' Total Assets of $292.36 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Atrium Therapeutics and its competitors. Atrium Therapeutics's current Total Assets is $292.36 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrium Therapeutics stock overvalued right now?
Atrium Therapeutics (RNA) has a current Total Assets of $292.36 Mil. The current Total Assets is $292.36 Mil. Atrium Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Atrium Therapeutics (RNA), the current Total Assets is $292.36 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atrium Therapeutics Business Description

Address 10578 Science Center Drive, Suite 125, San Diego, CA, USA, 92121
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
12GF Score

Get the complete analysis for RNA

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.80
Price